Meeting
2017 ASCO Annual Meeting
HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer.
Authors
Jason W.D. Hearn
University of Michigan, Ann Arbor, MI
Jason W.D. Hearn , Wanling Xie , Mari Nakabayashi , Nima Almassi , Chad A. Reichard , Mark Pomerantz , Philip W. Kantoff , Nima Sharifi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5050)
DOI
10.1200/JCO.2017.35.15_suppl.5050
Abstract #
5050
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase III trial comparing long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: GICOR protocol DART01/05.
First Author: A. Zapatero
Poster
2019 Genitourinary Cancers Symposium
Optimizing the use of androgen deprivation therapy in men with localized intermediate risk prostate cancer in the era of modern dose-escalated radiation therapy.
First Author: Sagar Anil Patel
Poster
2016 ASCO Annual Meeting
Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
First Author: Bernard M. Dubray
Poster
2024 ASCO Genitourinary Cancers Symposium
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life.
First Author: Sagar A. Patel